Hematopoietic Cell Transplantation May Be Effective for High-Risk Acute Myeloid Leukemia
the Cancer Therapy Advisor take:
Hematopoietic cell transplantation (HCT) may be an effective treatment for patients with high-risk acute myeloid leukemia (AML), according to a study published in Leukemia.
Researchers led by Johannes Schetelig, DKMS, of the German Bone Marrow Donor Center in Dresden examined 1,179 patients with intermediate- to high-risk AML. Allogeneic HCT was recommended in high-risk AML to be administered for aplasia after induction chemotherapy.
Patients were also randomized to one of two groups: a control group involved sibling HCT in first complete remission as well as matched, unrelated HCT in complex karyotype AML, or an experimental group where matched, unrelated HCT in first remission was also offered to patients with FMS-like tyrosine kinase 3-internal tandem duplication.
The researchers found that overall survival was significantly improved in high-risk patients after allogeneic HCT in aplasia and after HCT in remission. As-treated analysis also suggested a profound effect of allogeneic HCT on overall survival and even-free survival.
“Although superiority of one study arm could not be demonstrated in the intent-to-treat analaysis, secondary analysis suggest that early allogeneic HCT is a promising strategy for patients with high-risk AML,” the authors concluded.
Hematopoietic cell transplantation may be an effective treatment for patients with high-risk acute myeloid leukemia.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed